Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity. NICE technology appraisal guidance 589
National Institute for Health and Care Excellence (NICE)
Record ID 32018011645
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta589
Year Published:
2019
URL for published report:
https://www.nice.org.uk/guidance/ta589
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Antineoplastic Agents
- Antibodies, Bispecific
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.